Development and characterization of bladder cancer patient- derived xenografts for molecularly guided targeted therapy

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Pan, Chong Xian ^a   Zhang, Hongyong ^a   Tepper, C G ^a   Lin, Tzu Yin ^a   Davis, Ryan R ^a   Keck, James ^a   Ghosh, Paramita M ^a   Gill, Parkash ^a   Airhart, Susan ^a   Bult, Carol ^a   Gandara, David R ^a   Liu, Edison ^a   De Vere White, Ralph W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACTOLISIB; DNA; GEMCITABINE; INFIGRATINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PONATINIB; PROTEIN KINASE B; RNA; IMIDAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; TUMOR PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER MORPHOLOGY; CONTROLLED STUDY; DNA ISOLATION; DRUG EFFICACY; EXOME; FEMALE; HUMAN; HUMAN TISSUE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MOUSE; NEXT GENERATION SEQUENCING; NOD SCID GAMMA MOUSE; NONHUMAN; PROGRESSION FREE SURVIVAL; RNA ISOLATION; RNA SEQUENCE; TUMOR BIOPSY; TUMOR XENOGRAFT; VERY ELDERLY; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CLINICAL TRIAL; DRUG EFFECTS; DRUG SCREENING; GENETICS; MALE; METABOLISM; MULTICENTER STUDY; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS; XENOGRAFT;

ANIMALS; FEMALE; HETEROGRAFTS; HUMANS; IMIDAZOLES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PYRIDAZINES; QUINAZOLINES; QUINOLINES; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942874576     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134346     Document Type: Article

References (51)

1. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66: 4-34. pmid:16399414 doi: 10.1016/j.urology.2005.07.062
2. Carter AJ, Nguyen CN (2012) A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding. BMC Public Health 12: 526. pmid:22800364 doi: 10.1186/1471245812526
3. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF, et al. (1989) Superficial bladder cancer treated with bacillus CalmetteGuerin: a multivariate analysis of factors affecting tumor progression. J Urol 141: 22-29. pmid:2908949
4. Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley J, et al. (2013) Recurrence of highrisk bladder cancer: a populationbased analysis. Cancer 119: 3219-3227. doi: 10.1002/cncr.28147. pmid:23737352
5. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ, et al. (1999) 5year followup of a randomized prospective study comparing mitomycin C and bacillus CalmetteGuerin in patients with superficial bladder carcinoma. SwedishNorwegian Bladder Cancer Study Group. J Urol 161: 1124-1127. pmid:10081852 doi: 10.1016/s00225347( 01)616070
6. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore M, et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077. pmid:11001674
7. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84: 1424-1431. pmid:11355958 doi: 10.1054/bjoc.2001.1796
8. Avis NE, Deimling GT (2008) Cancer survivorship and aging. Cancer 113: 3519-3529. doi: 10.1002/cncr.23941. pmid:19058151
9. Avis NE, Smith KW, McGraw S, Smith RG, Petronis VM, Carver CS, et al. (2005) Assessing quality of life in adult cancer survivors (QLACS). Qual Life Res 14: 1007-1023. pmid:16041897 doi: 10.1007/s1113600421472
10. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29. doi: 10.3322/caac.20138. pmid:22237781
11. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. (2014) Personalized medicine for patients with advanced cancer in the phase I program at MD anderson: validation and landmark analyses. Clin Cancer Res 20: 4827-4836. doi: 10.1158/10780432. CCR140603. pmid:24987059
12. Andre F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, et al. (2014) Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 15: 267-274. doi: 10.1016/S14702045( 13)706119. pmid:24508104
13. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. (2011) The genomic complexity of primary human prostate cancer. Nature 470: 214-220. doi: 10.1038/nature09744. pmid:21307934
14. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471: 467-472. doi: 10.1038/nature09837. pmid:21430775
15. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, et al. (2011) Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 43: 875-878. doi: 10.1038/ng.907. pmid:21822268
16. Cancer Genome Atlas Research N (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615. doi: 10.1038/nature10166. pmid:21720365
17. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. (2012) Differential gene and transcript expression analysis of RNAseq experiments with TopHat and Cufflinks. Nat Protoc 7: 562-578. doi: 10.1038/nprot.2012.016. pmid:22383036
18. Conway T, Wazny J, Bromage A, Tymms M, Sooraj D, Williams ED, et al. (2012) Xenome-a tool for classifying reads from xenograft samples. Bioinformatics 28: i172-178. doi: 10.1093/bioinformatics/bts236. pmid:22689758
19. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biol 10: R25. doi: 10.1186/gb2009103r25. pmid:19261174
20. Trapnell C, Pachter L, Salzberg SL (2009) TopHat: discovering splice junctions with RNASeq. Bioinformatics 25: 1105-1111. doi: 10.1093/bioinformatics/btp120. pmid:19289445
21. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. (2010) Transcript assembly and quantification by RNASeq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28: 511-515. doi: 10.1038/nbt.1621. pmid:20436464
22. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows Wheeler transform. Bioinformatics 25: 1754-1760. doi: 10.1093/bioinformatics/btp324. pmid:19451168
23. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing nextgeneration DNA sequencing data. Genome Res 20: 1297-1303. doi: 10.1101/gr.107524.110. pmid:20644199
24. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. (2011) A framework for variation discovery and genotyping using nextgeneration DNA sequencing data. Nat Genet 43: 491-498. doi: 10.1038/ng.806. pmid:21478889
25. Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507: 315-322. doi: 10.1038/nature12965. pmid:24476821
26. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, et al. (2013) Wholegenome and wholeexome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 45: 1459-1463. doi: 10.1038/ng.2798. pmid:24121792
27. Tamborero D, GonzalezPerez A, PerezLlamas C, DeuPons J, Kandoth C, Reimand J, et al. (2013) Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep 3: 2650. doi: 10.1038/srep02650. pmid:24084849
28. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57. doi: 10.1038/nprot.2008.211. pmid:19131956
29. Turo R, Harnden P, Thygesen H, Fleischmann A, Thalmann GN, Seiler R, et al. (2014) FGFR3 Expression in Primary Invasive Bladder Cancers and Matched Lymph Node Metastases. J Urol. doi: 10.1016/j.juro.2014.06.026
30. Wang S, Zhang H, Cheng L, Evans C, Pan CX (2010) Analysis of the cytotoxic activity of carboplatin and gemcitabine combination. Anticancer Res 30: 4573-4578. pmid:21115908
31. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr., Tsao A, et al. (2011) The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1: 44-53. doi: 10.1158/21598274. CD100010. pmid:22586319
32. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. (2002) Efficacy and safety of trastuzumab as a single agent in firstline treatment of HER2overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726. pmid:11821453 doi: 10.1200/jco.20.3.719
33. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819. doi: 10.1056/NEJMoa1002011. pmid:20818844
34. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516. doi: 10.1056/NEJMoa1103782. pmid:21639808
35. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. (2003) Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med 348: 994-1004. pmid:12637609 doi: 10.1056/nejmoa022457
36. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, LObo C, et al. (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: 2251-2259. doi: 10.1056/NEJMoa0912614. pmid:20525993
37. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. (2009) Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957. doi: 10.1056/NEJMoa0810699. pmid:19692680
38. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. (2012) Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutationpositive nonsmallcell lung cancer (EURTAC): a multicentre, openlabel, randomised phase 3 trial. Lancet Oncol 13: 239-246. doi: 10.1016/S14702045(11)70393X. pmid:22285168
39. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73. pmid:15737014 doi: 10.1371/journal.pmed.0020073
40. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. (2013) Endocrinetherapyresistant ESR1 variants revealed by genomic characterization of breastcancerderived xenografts. Cell Rep 4: 1116-1130. doi: 10.1016/j.celrep.2013.08.022. pmid:24055055
41. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, et al. (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patientderived human breast cancer xenograft models. Cancer Res 73: 4885-4897. doi: 10.1158/00085472. CAN124081. pmid:23737486
42. Marangoni E, VincentSalomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al. (2007) A new model of patient tumorderived breast cancer xenografts for preclinical assays. Clin Cancer Res 13: 3989-3998. pmid:17606733 doi: 10.1158/10780432. ccr070078
43. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339: 1546-1558. doi: 10.1126/science.1235122. pmid:23539594
44. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. (2009) A primary xenograft model of smallcell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 69: 3364-3373. doi: 10.1158/00085472. CAN084210. pmid:19351829
45. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, et al. (2007) Identification of genotypecorrelated sensitivity to selective kinase inhibitors by using highthroughput tumor cell line profiling. Proc Natl Acad Sci U S A 104: 19936-19941. pmid:18077425 doi: 10.1073/pnas.0707498104
46. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607. doi: 10.1038/nature11003. pmid:22460905
47. Walrath JC, Hawes JJ, Van Dyke T, Reilly KM (2010) Genetically engineered mouse models in cancer research. Adv Cancer Res 106: 113-164. doi: 10.1016/S0065230X( 10)060045. pmid:20399958
48. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. (2014) Patientderived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4: 998-1013. doi: 10.1158/21598290. CD140001. pmid:25185190
49. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. (2012) Patientderived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9: 338-350. doi: 10.1038/nrclinonc.2012.61. pmid:22508028
50. Siolas D, Hannon GJ (2013) Patientderived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 73: 5315-5319. doi: 10.1158/00085472. CAN131069. pmid:23733750
51. Houghton JA, Taylor DM (1978) Growth characteristics of human colorectal tumours during serial passage in immunedeprived mice. Br J Cancer 37: 213-223. pmid:629859 doi: 10.1038/bjc.1978.29